Guardant Health, Inc. (NASDAQ:GH) Receives $48.21 Average PT from Analysts

Guardant Health, Inc. (NASDAQ:GH) has been assigned an average rating of “Buy” from the nineteen ratings firms that are currently covering the firm, Marketbeat Ratings reports. Nineteen investment analysts have rated the stock with a buy rating. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $48.21.

A number of research firms have issued reports on GH. Canaccord Genuity Group upped their price target on shares of Guardant Health from $42.00 to $60.00 and gave the company a “buy” rating in a report on Monday, February 24th. Raymond James restated an “outperform” rating and set a $59.00 target price (up previously from $39.00) on shares of Guardant Health in a research note on Friday, February 21st. Scotiabank raised their target price on Guardant Health from $47.00 to $52.00 and gave the company a “sector outperform” rating in a report on Monday, February 24th. The Goldman Sachs Group upped their price target on Guardant Health from $49.00 to $56.00 and gave the stock a “buy” rating in a report on Friday, February 21st. Finally, Piper Sandler increased their price objective on Guardant Health from $34.00 to $50.00 and gave the company an “overweight” rating in a research report on Wednesday, February 26th.

Insider Activity at Guardant Health

In related news, Director Musa Tariq sold 2,320 shares of Guardant Health stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $35.00, for a total transaction of $81,200.00. Following the completion of the transaction, the director now directly owns 2,676 shares of the company’s stock, valued at $93,660. This trade represents a 46.44 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have sold a total of 2,668 shares of company stock valued at $95,208 over the last quarter. 5.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. R Squared Ltd acquired a new stake in shares of Guardant Health in the 4th quarter valued at $26,000. JNBA Financial Advisors bought a new position in Guardant Health in the third quarter valued at about $26,000. SBI Securities Co. Ltd. acquired a new stake in Guardant Health in the fourth quarter worth about $43,000. Ashton Thomas Securities LLC acquired a new stake in Guardant Health in the third quarter worth about $34,000. Finally, Kimelman & Baird LLC bought a new stake in Guardant Health during the 4th quarter worth about $58,000. Institutional investors and hedge funds own 92.60% of the company’s stock.

Guardant Health Stock Performance

GH opened at $40.74 on Friday. The firm has a market cap of $5.03 billion, a P/E ratio of -11.44 and a beta of 1.32. The business has a 50 day moving average price of $41.09 and a 200 day moving average price of $32.01. Guardant Health has a twelve month low of $15.81 and a twelve month high of $50.89.

Guardant Health (NASDAQ:GH) last released its quarterly earnings results on Thursday, February 20th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.15). The firm had revenue of $201.81 million during the quarter, compared to the consensus estimate of $192.50 million. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. As a group, analysts anticipate that Guardant Health will post -2.9 earnings per share for the current fiscal year.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.